 |
 |
Penny Stock Fortunes -- January 2007 Doctors Will Use Monogram’s Tests Because They Work 100% of the Time Published studies prove Monogram’s products work immeasurably better than other currently available tests. In fact, Monogram presented the results of these studies at the International AIDS Conference in Toronto. Monogram’s Trofile test accurately measured a panel of 46 strains of HIV, including multiple subtypes of the virus. The test correctly identified all 46 strains tested. That’s a 100% accuracy rate! Trofile was also accurate when tested against three cloned viruses. Another test compared the abilities of widely used genetics tests to Monogram’s Trofile to accurately identify strains of HIV. The other tests were only about 65% accurate and, according to Monogram scientists, even less accurate in many cases. These results alone prove that the Monogram’s tests are far superior. After all, if big drug companies like Merck and Pfizer had the ability to replicate these stellar testing results, do you think they would pay a tiny $220 million company to do it for them? Fat chance. Bonus Profit Potential: Better Cancer Treatments for Millions Hoping to build on top of its state-of-the-art HIV diagnostic systems, Monogram has developed a test to foster personalized care for cancer patients. Over 1 million new cases of solid tumor cancer are diagnosed each year in the United States. And there are four cancer types — breast, prostate, lung and colorectal — that make up approximately 700,000 of those newly diagnosed cases. According to Monogram, “Health care providers have a critical unmet need for more accurate prognostic and diagnostic tools and more effective, safer therapeutics.” That’s why Monogram has developed its eTag technology. It basically does for cancer treatment what the Trofile test does for HIV. The testing system that will allow drug companies to better design clinical trials and help individual physicians better treat their patients by providing more personal care. Monogram acquired the technology for eTag from its 2004 merger with ACLARA Biosciences. The goal of the merger was to expand Monogram’s portfolio of products in order for the company to take advantage of the growing trend of personal medicine in oncology. All together, Monogram has a powerful advantage in a very important industry. With the best tests available and Big Pharma knocking at its door, Monogram is don’t overuse to take off in personalized medicine. Several major drug manufacturers have recognized its potential, and now it’s your turn to get in before the rest of the world takes notice. Action to take: Buy shares of Monogram Biosciences (MGRM: NASDAQ) under $1.95. Do not chase the price. If the price dips below $1.30 per share, sell your shares. A quick note about stop losses: When it comes to penny stocks, it’s always a good idea to set stop losses as an insurance policy for your portfolio. That’s why you should limit your losses to 25% should a stock take a fall. It keeps your losing positions from overtaking your winning ones. This way, you’ll keep more of your gains from the stocks that take off.
|
|
